001     821621
005     20230213130020.0
024 7 _ |a G:(EU-Grant)675451
|d 675451
|2 CORDIS
024 7 _ |a G:(EU-Call)H2020-EINFRA-2015-1
|d H2020-EINFRA-2015-1
|2 CORDIS
024 7 _ |a corda__h2020::675451
|2 originalID
035 _ _ |a G:(EU-Grant)675451
150 _ _ |a A Centre of Excellence in Computational Biomedicine
|y 2016-10-01 - 2019-09-30
371 _ _ |a University of Sheffield
|b University of Sheffield
|d United Kingdom
|e http://www.sheffield.ac.uk/
|v CORDIS
371 _ _ |a LIFETEC GROUP BV
|b LIFETEC GROUP
|d Netherlands
|v CORDIS
371 _ _ |a THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
|b UOXF
|d United Kingdom
|e http://www.ox.ac.uk
|v CORDIS
371 _ _ |a Edinburgh Napier University
|b Edinburgh Napier University
|d United Kingdom
|e http://www.napier.ac.uk/alumni/Pages/home.aspx
|v CORDIS
371 _ _ |a CBK SCI CON LIMITED
|d United Kingdom
|e http://www.cbkscicon.com
|v CORDIS
371 _ _ |a ACELLERA LABS SL
|b ACELLERA LABS SL
|d Spain
|e http://www.acellera.com
|v CORDIS
371 _ _ |a EVOTEC AG*
|d Germany
|v CORDIS
371 _ _ |a University of London - University College London
|b UCL
|d United Kingdom
|e http://www.ucl.ac.uk/
|v CORDIS
371 _ _ |a JANSSEN PHARMACEUTICA NV
|d Belgium
|e http://www.janssen.com/
|v CORDIS
371 _ _ |a Reprotec UK Limited
|d United Kingdom
|v CORDIS
371 _ _ |a BULL SAS
|b BULL
|d France
|e http://www.bull.com
|v CORDIS
371 _ _ |a SURFSARA BV
|d Netherlands
|e http://www.sara.nl
|v CORDIS
371 _ _ |a University of Geneva
|b UNIGE
|d Switzerland
|e https://www.unige.ch/
|v CORDIS
371 _ _ |a Pompeu Fabra University
|b UPF
|d Spain
|e http://www.upf.edu/en/
|v CORDIS
371 _ _ |a BARCELONA SUPERCOMPUTING CENTER - CENTRO NACIONAL DE SUPERCOMPUTACION
|b BSC
|d Spain
|e http://www.bsc.es
|v CORDIS
371 _ _ |a VU University Amsterdam
|b VU
|d Netherlands
|e http://www.vu.nl/en/
|v CORDIS
372 _ _ |a H2020-EINFRA-2015-1
|s 2016-10-01
|t 2019-09-30
450 _ _ |a CompBioMed
|w d
|y 2016-10-01 - 2019-09-30
510 1 _ |0 I:(DE-588b)5098525-5
|a European Union
|2 CORDIS
680 _ _ |a This Centre of Excellence will advance the role of computationally based modelling and simulation within biomedicine. Three related user communities lie at the heart of the CoE: academic, industrial and clinical researchers who all wish to build, develop and extend such capabilities in line with the increasing power of high performance computers. Three distinct exemplar research areas will be pursued: cardiovascular, molecularly-based and neuro-musculoskeletal medicine. Predictive computational biomedicine involves applications that are comprised of multiple components, arranged as far as possible into automated workflows in which data is taken, from an individual patient, processed, and combined into a model which produces predicted health outcomes. Many of the models are multiscale, requiring the coupling of two or more high performance codes. Computational biomedicine holds out the prospect of predicting the effect of personalised medical treatments and interventions ahead of carrying them out, with all the ensuing benefits. Indeed, in some cases, it is already doing so today. The CoE presents a powerful consortium of partners and has an outward facing nature and will actively train, disseminate and engage with these user communities across Europe and beyond. Because this field is new and growing rapidly, it offers numerous innovative opportunities. There are three SMEs and three enterprises within the project, as well as eight associate partners drawn from across the biomedical sector, who are fully aware of the vast potential of HPC in this domain. We shall work with them to advance the exploitation of HPC and will engage closely with medical professionals through our partner hospitals in order to establish modeling and simulation as an integral part of clinical decision making. Our CoE is thus user-driven, integrated, multidisciplinary, and distributed; presenting a vision that is in line with the Work Programme.
909 C O |o oai:juser.fz-juelich.de:821621
|p authority:GRANT
|p authority
970 _ _ |a oai:dnet:corda__h2020::d00f428c0a55a34a8113cc73033e3e45
980 _ _ |a G
980 _ _ |a CORDIS
980 _ _ |a AUTHORITY


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21